(2023) demonstrated a clinically meaningful advantage of CD19 CAR-T therapy over donor lymphocyte infusion in achieving complete remission for relapsed/refractory acute lymphoblastic leukemia (OR: 4.12, 95% CI: 1.04–16.37; high-quality evidence; Figure 1) (49). Here, CD19 is linked to acute lymphoblastic leukemia.